How much can GenAI improve accuracy in literature summarization?
- Sushma Dharani
- Dec 13, 2025
- 6 min read
Pharmacovigilance (PV) depends on accurate, timely synthesis of literature — published case reports, clinical trials, regulatory communications, and real-world evidence — to detect, assess, and mitigate drug safety risks. Traditionally, teams have run manual or semi-automated literature screens, extracted relevant facts, and assembled safety narratives. That process is slow, expensive, and error-prone: missed mentions, duplicated case reports, inconsistent terminology, and human fatigue all reduce sensitivity and the reliability of summaries. Generative AI (GenAI) and modern large language models (LLMs) promise to change that calculus. But how much can GenAI actually improve accuracy in literature summarization for pharmacovigilance? The pragmatic answer is: substantially, when applied thoughtfully and governed properly — but not perfectly, and only when paired with domain expertise and strong validation. Below I explain the areas of measurable improvement, typical limitations, how measurement should be done, and how a specialist provider such as Tesserblu can help operationalize safe, accurate GenAI summarization for PV teams.
Where GenAI adds the most accuracy — concrete mechanisms
Better named-entity recognition and normalization: Modern LLMs plus task-specific fine-tuning improve extraction of drug names, dosages, routes, outcomes, and temporal relationships from free text. That reduces false negatives (missed adverse event mentions) and false positives from ambiguous wording, because LLMs are better at context-sensitive interpretation than older keyword filters or rule engines. Multiple recent reviews document how NLP and GenAI techniques increase the sensitivity and utility of unstructured text mining in PV.
Improved deduplication and case linkage: Literature often cites the same adverse event more than once (conference abstract, journal, regulatory report). Advanced models can identify near-duplicates even across paraphrases and link them to a single safety signal — reducing inflation of evidence counts and improving precision in summaries. Industry case studies and vendor writeups show meaningful reductions in manual workload by automating deduplication and triage.
Contextual summarization and reasoning across sources: GenAI can synthesize across multiple articles and produce coherent, evidence-anchored summaries (e.g., “Three cohort studies and two case series report similar patterns of hepatotoxicity, onset 2–6 weeks, reversible on discontinuation”). When constrained by retrieval and citation grounding, this capability reduces omission errors that occur when reviewers fail to connect dispersed evidence. Reviews of GenAI/LLM application in healthcare identify cross-document synthesis as a key benefit for tasks like signal management.
Multilingual coverage and scale: PV teams need global surveillance. GenAI models trained for multilingual understanding can surface findings from non-English literature or local regulatory reports that keyword approaches miss — increasing recall and therefore the completeness of summaries. Vendor offerings and sector reports emphasize multilingual NLP as a major contributor to enhanced surveillance.
Quantitatively, improvements will vary by dataset and task. Published studies and scoping reviews report that NLP/ML pipelines can markedly improve detection sensitivity and reduce manual review time — the exact uplift in accuracy depends on baseline processes, how models are tuned, and whether post-processing and human QA are used. In practical deployments, organizations commonly report major drops in false negatives and meaningful reductions in review backlog when GenAI is integrated into literature workflows.
Key limitations that temper accuracy gains
GenAI is not a magic wand. There are important failure modes that can actually harm perceived accuracy unless mitigated:
Hallucinations and unsupported assertions: LLMs can generate plausible but false statements (e.g., inventing study details or overstating causal claims). For pharmacovigilance, where regulatory action may follow, hallucinations are unacceptable unless every generated claim is anchored to verifiable citations and provenance. Regulatory guidance and working groups are explicitly flagging the need for provenance and audit trails when using LLMs in PV.
Domain mismatch and rare events: Adverse events that are rare or described with idiosyncratic language may still be missed or misclassified without domain-specific fine-tuning and controlled vocabularies (MedDRA, WHO-ART). Generic LLMs need careful adapters or retrieval augmentation to perform well on niche PV concepts.
Data drift and model aging: Medical terminology, regulatory requirements, and the literature corpus change. Models must be maintained, re-validated, and retrained periodically; otherwise accuracy will degrade. Governance frameworks advise lifecycle control and monitoring for AI models used in safety-critical contexts.
Evaluation complexity: Measuring “accuracy” in summarization is nontrivial — should you measure fact extraction precision/recall, summary faithfulness, or downstream signal detection performance? Different metrics produce different impressions of improvement; robust evaluation must include multiple metrics and human adjudication.
How to measure accuracy improvements rigorously
To meaningfully claim accuracy gains from GenAI summarization, PV teams should adopt a structured evaluation plan:
Define the use case and dominant failure modes: Is the goal exhaustive literature surveillance, prioritization for case review, or drafting regulatory narratives? Each has different tolerances for false positives/negatives.
Use gold standard corpora and prospectively collected test sets: Annotated datasets with explicit entity labels, event relationships, and human-written summaries are essential. Where possible, include edge cases and multilingual examples.
Report multiple metrics: For extraction: precision, recall, F1. For summarization: ROUGE/BLEU are insufficient alone — add fact-level accuracy (does each claim map to a cited source?), hallucination rate, and human expert rating of utility. Also measure downstream impact: time saved, change in signal detection sensitivity, or changes in the number of meaningful signals flagged.
Human-in-the-loop auditing: Combine model outputs with SME review during a validation window; track corrections and use them to bootstrap iterative re-training.
Regulatory-grade documentation: Maintain audit logs, versioning, and provenance so that each automated conclusion can be traced back to source documents and model versions. This is increasingly emphasized in industry guidance.
Operational best practices to maximize safe accuracy
To translate algorithmic gains into real-world accuracy, organizations should:
Use retrieval-augmented generation (RAG). Constrain LLM outputs to retrieved, indexed passages from the literature so summaries are grounded in verifiable text, minimizing hallucination.
Incorporate controlled vocabularies and ontologies. Normalize extracted terms to MedDRA/WHO-ART and standard drug dictionaries to avoid terminological drift.
Apply conservative summarization templates. Force outputs into evidence tables and template language (e.g., “X study (n=Y) reported Z; limitations: …”) that make claims explicit and citable.
Layer automated QA checks. Automated cross-checks (date consistency, numeric consistency, citation matching) catch common generation errors before review.
Keep humans where it matters. Use GenAI to triage, draft, and surface candidate signals; preserve final decision and regulatory narrative drafting for qualified safety experts.
How Tesserblu can help
Tesserblu is a vendor focused on life-sciences technology and pharmacovigilance workflows. Their public materials describe a suite of products and services targeted at exactly the problems GenAI tries to solve in PV: automated intake and case processing, AI-assisted signal engines, deduplication, multilingual NLP, and tools to streamline post-marketing commitments and reporting. Tesserblu positions these capabilities as designed to reduce manual workload (their materials and blog posts cite reductions up to 50% in certain workflow stages) while integrating governance and expert oversight.
Concretely, Tesserblu can help PV teams by:
Implementing retrieval and ingestion pipelines that bring literature, regulatory notices, and internal reports into a managed, indexed repository — the foundation for reliable GenAI summarization. Their product descriptions discuss automated intake and drug safety database integration.
Providing domain-tuned NLP and deduplication modules so extracted entities are normalized to MedDRA and duplicate reports are linked automatically — reducing the noise that causes inaccurate summaries. Their public posts highlight deduplication and consistent keyword detection as product features.
Delivering AI-powered signal engines and triage workflows that prioritize literature and case reports for human review, allowing safety teams to focus SMEs where they add the most value. Their thought pieces and case materials describe workload reduction through AI signal detection.
Helping with governance and validation by integrating audit logs, version control, and human review checkpoints so GenAI outputs meet regulatory expectations. Tesserblu’s “about us” and product pages emphasize compliance and domain expertise in PV deployments.
A practical approach is to start with a pilot: feed a curated historical corpus, run Tesserblu’s ingestion + GenAI summarization pipeline, and compare outputs to prior human summaries and regulatory narratives using the evaluation plan above. Iteratively refine prompts, entity normalization, and QA rules until the system consistently improves sensitivity and reduces false claims. Tesserblu’s mix of product features and PV domain focus makes them a plausible partner for such pilots.
Reasonable expectations and roadmap
What should teams realistically expect?
Short term (months): Significant reductions in manual triage work, better recall of dispersed literature, and faster draft summaries that accelerate SME review. Expect measurable time savings and improvements in extraction F1 scores when models are properly fine-tuned and validated.
Medium term (6–18 months): As governance, retraining, and feedback loops mature, expect improved faithfulness of summaries, broader multilingual coverage, and fewer post-release corrections. Tools that combine RAG, templates, and constrained generation will become standard practice.
Long term: GenAI becomes a dependable augmentation layer for PV, but human oversight remains essential. Regulatory frameworks and industry guidance will continue to shape acceptable practice, especially around provenance and auditability.
Conclusion
Generative AI can materially improve the accuracy of literature summarization in pharmacovigilance — primarily by increasing recall (finding relevant evidence), improving entity extraction and normalization (reducing classification errors), deduplicating dispersed reports (improving precision of evidence counts), and synthesizing across documents (making summaries more complete). Those gains, however, depend on careful engineering: grounding summaries in retrieved sources, normalizing to controlled vocabularies, running conservative templates, and maintaining human-in-the-loop validation and governance. Vendors such as Tesserblu offer domain-focused platforms and AI modules that address many of these needs, and they can be effective partners for pilots and scaled deployments when paired with robust evaluation and regulatory documentation. Book a meeting if you are interested to discuss more.
Comments